Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update

89% of evaluable mipletamig patients achieve remission in combination therapy for frontline AML across two trialsIntroduces first trispecific molecules, APVO451 and APVO452, advancing therapies designed to overcome immune suppression in certain …
Jetzt den vollständigen Artikel lesen